Search Results
Aug 05, 2026, 09:07 ET Facteus Expands Investor Product Suite With Bigger, Broader Data Coverage
playersMore than 8 million distinct UPCsMore than $265 billion in annual spendingApproximately 99% data fill by T+3More than four years of historyOnline and offline spend, discounts, tender type, brand, category and ticker metricsThe
More news about: Facteus
Aug 05, 2026, 09:02 ET Francis Medical Announces Northwell Urology Group Performs First Commercial Vanquish® Water Vapor Ablation Procedure in New York
call (763) 951-0370.ReferenceGeorge A, Giesler E, Mazzarella B, Levin R, Frendl D, Warlick C, Given R, Kella N, Frye T, Mynderse L, Kasraeian A, Milbank A, Nabbout P, Grunberger I, Rastinehad A, Schwart M, Wysock J, Rousseau M, Pliskin M, Satkunasivam R, Rich D, Shore
More news about: Francis Medical, Inc.
Aug 05, 2026, 09:02 ET Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
taxane-based therapy for metastatic hormone-sensitive disease. Some participants were exposed to an experimental prostate-specific membrane antigen (PSMA) T-Cell Engager prior to their enrolment into the SECuRE study. The median number of treatment cycles of 67Cu-SAR-bisPSMA across participants
More news about: Clarity Pharmaceuticals
Aug 05, 2026, 08:45 ET Molex Introduces MiniMix Hybrid Power and Signal Connectors to Accelerate Humanoid Robotics Mass-Production Scaling
Molex MiniMix Hybrid Power and Signal Connectors resolve these manufacturing challenges by consolidating up to 15.0A power contacts and 1Gbps 1000BASE-T1 Ethernet communication into a single integrated interface. Featuring an ultra-compact 5.65mm routing profile, MiniMix is the industry's smallest hybrid
More news about: Molex Incorporated
Aug 05, 2026, 08:44 ET iBase-t Invests in Customer Outcomes with Launch of Value Realization Organization
and Lean Kaizen credentials from GE Aerospace.About iBase-tiBase-t is the global leader in cloud software for the aerospace and defense industry. Committed to innovation, customer success, and product excellence, iBase-t ensures digital continuity across manufacturing, quality, and
More news about: iBase-t
Aug 05, 2026, 08:00 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Advanced provides CDMO services for a broad spectrum of CGT products, including plasmids, lentivirus, cell therapies (CAR-T, TCR-T, UCAR-T, NK, CAR-NK, MSC, TIL, iPSC, etc.), in vivo CAR-T, mRNA, and exosomes. This supports clients across the entire CGT product lifecycle, from IND filing and clinical
More news about: Porton Advanced
Aug 05, 2026, 08:00 ET Study Finds Blood-Based Breast Cancer Detection Can Create Value for Patients and Healthcare Systems
pathways, particularly for women with dense breasts", said Dr. Edith A. Perez, Professor Emeritus, Mayo Clinic.About the StudyJacie T. Cooper , Alan Hollingsworth , Randy D. Moore , Cheryl Croft, John Schneider, Kristina D. Rinker, Eldon Spackman, Cost-effectiveness of biennial breast
More news about: Syantra Inc.
Aug 05, 2026, 07:40 ET Carolinas' Construction Industry Leaders Honored
a licensed Professional Engineer in North Carolina. Jonathan began his career with the North Carolina Department of Transportation before joining S. T. Wooten Corporation in 1987. For four decades, he has served in key leadership roles and is currently the Vice President responsible for the Engineering
More news about: Carolinas AGC
Aug 05, 2026, 07:31 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
now, we have successfully supported our clients to secure 26 global IND approvals from NMPA, FDA, and Medsafe, including the first in vivo CAR-T therapy to receive IND clearance in China. Additionally, Porton Advanced has accumulated extensive experience managing 12 programs in Phase I/II or commercial-stage
More news about: Porton Advanced
Aug 05, 2026, 06:59 ET Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.For more information, visit www.Q32Bio.com.1National
More news about: Q32 Bio
Aug 05, 2026, 06:26 ET HighByte Positioned as a Leader & Emerging Innovator in the SPARK Matrix™: Industrial Data Management (IDM) Platform, 2026 by QKS Group
Ignatius Daniel T, Principal Analyst at QKS Group, said, "HighByte continues to strengthen its position in the Industrial Data Management market through its purpose-built
More news about: QKS Group
Aug 05, 2026, 05:39 ET 雲頂新耀將於2026年8月19日公佈2026年度中期業績並舉行線上投資人會議
441213680466電話參會密碼：834993同聲傳譯（英文）鏈接：網絡參會：https://clsa.zoom.com/webinar/register/WN_CZKptYYzT5a-NKhgC7t7vw有關雲頂新耀雲頂新耀是一家專注於創新藥研發、臨床開
More news about: 雲頂新耀
Aug 05, 2026, 05:34 ET Everest Medicines to Announce 2026 Interim Results and Host Online Investor Call on August 19, 2026
Link: https://clsa.zoom.com/webinar/register/WN_CZKptYYzT5a-NKhgC7t7vwAbout Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering,
More news about: Everest Medicines
Aug 05, 2026, 03:00 ET NueCell Bio 宣佈正式成立，成為細胞治療領域嶄新的轉化夥伴，憑藉獨特專業知識加速治療方案從發現階段邁向 GMP 生產
由一支在先進治療市場擁有非凡經驗的團隊領導。團隊在支援客戶開發新型細胞治療方面擁有業界領先的專業知識，使 NueCell Bio 能夠為各類細胞治療提供可訂製的模組化技術，進行細胞工程改造，並開發可擴展、符合 GMP 標準的生產流程及分析方法。NueCell Bio 的業務範疇涵蓋此領域內廣泛而突破性的科學技術，包括 CAR-T、幹細胞、iPSC（誘導多能幹細胞）衍生療法、基因編輯細胞及組織修復平台，同時支援自體及異體產品。NueCell Bio 總部設於聖地牙哥的 Sorrento Valley地區，當地是生物科技及先進治療開發的領先樞紐，設有一座佔地26,300平方呎、專門提供細胞治療轉化服務的先進設施。NueCell Bio 行政總裁 Michael
More news about: NueCell Bio
Aug 05, 2026, 03:00 ET NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
processes and analytics for a wide range of cell therapies. NueCell Bio works across a broad spectrum of groundbreaking science in this field, including CAR-T, stem cells, iPSC-derived therapies, gene-edited cells, and tissue repair platforms – supporting both autologous and allogeneic products.NueCell
More news about: NueCell Bio
Aug 05, 2026, 03:00 ET NueCell Bio Announces its Launch as a New Translational Partner for Cell Therapies with Unique Expertise to Accelerate Treatments from Discovery into GMP Manufacturing
processes and analytics for a wide range of cell therapies. NueCell Bio works across a broad spectrum of groundbreaking science in this field, including CAR-T, stem cells, iPSC-derived therapies, gene-edited cells, and tissue repair platforms – supporting both autologous and allogeneic products.NueCell
More news about: NueCell Bio
Aug 05, 2026, 02:52 ET Chunghwa Telecom Reports Un-Audited Consolidated Operating Results for the Second Quarter of 2026
Company's T-IFRSs financial measures;these non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the Company's T-IFRSs financial measures;these non-GAAP financial measures should not be considered to be superior to the Company's T-IFRSs financial
More news about: Chunghwa Telecom Co., Ltd.
Aug 05, 2026, 02:11 ET Hard Rock Cafe und Coca-Cola® starten den Musikwettbewerb „Hard Rock Rising" für Nachwuchskünstler
of Individuality ein, der Streetwear-Marke, die für ihre Wurzeln in der Musikkultur bekannt ist. Gemeinsam werden die Marken ein „Hard Rock Rising"-T-Shirt und eine gemeinsame Bekleidungskollektion auf den Markt bringen.Künstler, die bereit sind, auf die Bühne zu gehen, können sich bis zum 18.
More news about: Hard Rock International
Aug 05, 2026, 02:04 ET Hard Rock Café et Coca-Cola® lancent le concours musical Hard Rock Rising à l'intention des artistes émergents
Cult of Individuality, la marque de streetwear réputée pour ses racines ancrées dans la culture musicale. Ensemble, les deux marques vont lancer un t-shirt Hard Rock Rising ainsi qu'une collection de vêtements en collaboration.Les artistes prêts à monter sur scène ont jusqu'au 18 août pour déposer
More news about: Hard Rock International
Aug 04, 2026, 18:53 ET GERDAU S.A. - INFORMAÇÕES CONSOLIDADAS
2026.Lucro líquido ajustado de R$ 1,5 bilhão no 2T26, 45% e 70% superior ao 1T26 e 2T25, respectivamente, em função das dinâmicas dos resultados operacionais e financeiros da Companhia.Investimentos (CAPEX) de R$ 1,0 bilhão no 2T26, atingindo, no acumulado de 6M26, 45% do
More news about: Gerdau S.A.
Aug 04, 2026, 16:15 ET EOG Resources Reports Second Quarter 2026 Results
Commentary"EOG delivered outstanding second quarter results, including record financial performance. Strong operational execution highlighted by LOE and GP&T costs below guidance midpoints coupled with higher oil prices drove this robust financial performance. In the second quarter, we generated $2.8 billion
More news about: EOG Resources, Inc.
Aug 04, 2026, 16:05 ET Compass, Inc. Reports Record Second Quarter 2026 Results
Title and Escrow ("T&E"): Total Title and Escrow transactions were 42,608 in Q2 2026 compared to T&E transactions of 7,881 in Q2 2025, an increase of 441% year-over-year primarily due to the addition of T&E transactions from Anywhere. T&E transactions increased by 7.6%
More news about: Compass, Inc.
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D).MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D.MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes,
More news about: Amgen
Aug 04, 2026, 15:28 ET Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
therapeutic programs.""BioSymetrics and BrainStorm bring complementary AI and translational capabilities to precision neuroscience," said Robert T. Fremeau, Jr., Ph.D., Founder and Chief Executive Officer of BrainStorm Therapeutics. "BioSymetrics identifies clinically meaningful Parkinson's disease
More news about: Lunai Bioworks Inc.